In This Article:
As the U.S. stock market navigates a "sometimes-bumpy path" toward its inflation target, as noted by Fed Chair Jerome Powell, investors are closely watching for opportunities amidst fluctuating indices. Penny stocks, though an older term, remain relevant by highlighting smaller or less-established companies that can offer substantial value. By focusing on those with strong financials and clear growth potential, investors may find promising opportunities within this often-overlooked segment of the market.
Top 10 Penny Stocks In The United States
| Name | Share Price | Market Cap | Financial Health Rating |
| BAB (OTCPK:BABB) | $0.8155 | $5.95M | ★★★★★★ |
| RLX Technology (NYSE:RLX) | $1.63 | $2.05B | ★★★★★★ |
| Flexible Solutions International (NYSEAM:FSI) | $3.72 | $52.54M | ★★★★★★ |
| QuantaSing Group (NasdaqGM:QSG) | $3.08 | $155.89M | ★★★★★★ |
| Golden Growers Cooperative (OTCPK:GGRO.U) | $4.50 | $69.71M | ★★★★★★ |
| So-Young International (NasdaqGM:SY) | $1.25 | $81.58M | ★★★★☆☆ |
| ZTEST Electronics (OTCPK:ZTST.F) | $0.24 | $8.98M | ★★★★★★ |
| PHX Minerals (NYSE:PHX) | $3.70 | $127.43M | ★★★★★☆ |
| Zynerba Pharmaceuticals (NasdaqCM:ZYNE) | $1.30 | $65.6M | ★★★★★☆ |
| CBAK Energy Technology (NasdaqCM:CBAT) | $0.94 | $83.45M | ★★★★★☆ |
Click here to see the full list of 748 stocks from our US Penny Stocks screener.
Let's explore several standout options from the results in the screener.
Cocrystal Pharma
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Cocrystal Pharma, Inc. is a biotechnology company dedicated to discovering and developing antiviral therapeutic treatments for serious and chronic viral diseases, with a market cap of $18.01 million.
Operations: Cocrystal Pharma, Inc. does not report any specific revenue segments.
Market Cap: $18.01M
Cocrystal Pharma, Inc., with a market cap of US$18.01 million, is a pre-revenue biotechnology company focused on antiviral treatments. Despite being debt-free and having short-term assets of US$19.7 million that cover both its short- and long-term liabilities, the company remains unprofitable with a negative return on equity of -103.09%. Recent earnings reports indicate increasing losses, with a net loss of US$4.94 million for Q3 2024 compared to US$4.17 million in the previous year. The management team is experienced but faces challenges as earnings are forecasted to decline over the next three years without expected profitability improvements.
PHX Minerals
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: PHX Minerals Inc. is a natural gas and oil mineral company operating in the United States with a market capitalization of $127.43 million.